Riley Timothy P, Chou Hui-Ting, Hu Ruozhen, Bzymek Krzysztof P, Correia Ana R, Partin Alexander C, Li Danqing, Gong Danyang, Wang Zhulun, Yu Xinchao, Manzanillo Paolo, Garces Fernando
Department of Therapeutics Discovery, Amgen Research, Amgen Inc., Thousand Oaks, CA, United States.
Department of Therapeutics Discovery, Amgen Research, Amgen Inc., South San Francisco, CA, United States.
Front Immunol. 2021 Apr 22;12:660198. doi: 10.3389/fimmu.2021.660198. eCollection 2021.
The worldwide pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is unprecedented and the impact on public health and the global economy continues to be devastating. Although early therapies such as prophylactic antibodies and vaccines show great promise, there are concerns about the long-term efficacy and universal applicability of these therapies as the virus continues to mutate. Thus, protein-based immunogens that can quickly respond to viral changes remain of continued interest. The Spike protein, the main immunogen of this virus, displays a highly dynamic trimeric structure that presents a challenge for therapeutic development. Here, guided by the structure of the Spike trimer, we rationally design new Spike constructs that show a uniquely high stability profile while simultaneously remaining locked into the immunogen-desirable prefusion state. Furthermore, our approach emphasizes the relationship between the highly conserved S2 region and structurally dynamic Receptor Binding Domains (RBD) to enable vaccine development as well as the generation of antibodies able to resist viral mutation.
由严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引起的全球大流行是前所未有的,对公共卫生和全球经济的影响仍然是毁灭性的。尽管早期疗法如预防性抗体和疫苗显示出巨大的前景,但随着病毒不断变异,人们对这些疗法的长期疗效和普遍适用性仍存在担忧。因此,能够快速响应病毒变化的基于蛋白质的免疫原仍然备受关注。刺突蛋白是这种病毒的主要免疫原,呈现出高度动态的三聚体结构,这对治疗性开发构成了挑战。在此,在刺突三聚体结构的指导下,我们合理设计了新的刺突构建体,这些构建体显示出独特的高稳定性,同时保持锁定在免疫原所需的预融合状态。此外,我们的方法强调了高度保守的S2区域与结构动态的受体结合域(RBD)之间的关系,以推动疫苗开发以及产生能够抵抗病毒突变的抗体。